Active	Status	Sponsor type	Region	Phase	Filter
21 Active 3 Inactive 24 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « September » « 2025 » M T W T F S S 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5   - « September » « 2025 » M T W T F S S 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ahmed, Ahmed
ADsolve, NCT07006792: A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden	Recruiting	4	200	Canada, US, RoW	Lebrikizumab, LY3650150	Eli Lilly and Company	Atopic Dermatitis	04/26	09/26
NCT06595823: Betadine Versus Saline in Swapping of Subcutaneous Tissue	Completed	N/A	300	RoW	Betadine, Saline	Egymedicalpedia, Al-Azhar University	Surgical Site Infection	03/23	03/23

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ahmed, Ahmed
ADsolve, NCT07006792: A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden	Recruiting	4	200	Canada, US, RoW	Lebrikizumab, LY3650150	Eli Lilly and Company	Atopic Dermatitis	04/26	09/26
NCT06595823: Betadine Versus Saline in Swapping of Subcutaneous Tissue	Completed	N/A	300	RoW	Betadine, Saline	Egymedicalpedia, Al-Azhar University	Surgical Site Infection	03/23	03/23